Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its Compensation Committee has granted stock options to two newly hired employees on January 2, 2025. The grants include options to purchase 45,000 shares of common stock at an exercise price of $3.00 per share, matching the closing price on Nasdaq Global Market on the grant date.
The options were granted under the company's 2022 Employment Inducement Incentive Award Plan, following Nasdaq Listing Rule 5635(c)(4). These 10-year term options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, contingent on continued employment.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) ha annunciato che il suo Comitato per la Compensazione ha concesso opzioni su azioni a due nuovi dipendenti assunto il 2 gennaio 2025. Le concessioni comprendono opzioni per acquistare 45.000 azioni ordinarie a un prezzo di esercizio di $3,00 per azione, corrispondente al prezzo di chiusura sul Nasdaq Global Market nella data della concessione.
Le opzioni sono state concesse ai sensi del Piano di Incentivazione per l'Occupazione 2022 dell'azienda, in conformità con la Regola di quotazione Nasdaq 5635(c)(4). Queste opzioni con termine di 10 anni matureranno in quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura mensilmente nei tre anni successivi, a condizione di continuare l'impiego.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) anunció que su Comité de Compensación ha otorgado opciones de acciones a dos nuevos empleados contratados el 2 de enero de 2025. Las concesiones incluyen opciones para comprar 45,000 acciones ordinarias a un precio de ejercicio de $3.00 por acción, coincidiendo con el precio de cierre en el Nasdaq Global Market en la fecha de otorgamiento.
Las opciones fueron otorgadas bajo el Plan de Incentivo por Empleo 2022 de la empresa, de acuerdo con la Regla de Listado Nasdaq 5635(c)(4). Estas opciones de 10 años se consolidarán en cuatro años, con un 25% consolidándose después del primer año y el 75% restante consolidándose mensualmente durante los tres años siguientes, sujeto a la continuación del empleo.
젠탈리스 제약 (Nasdaq: ZNTL)은 보상 위원회가 2025년 1월 2일에 두 명의 신규 직원에게 주식 옵션을 부여했다고 발표했습니다. 이 부여에는 주당 $3.00의 행사 가격으로 45,000주를 구매할 수 있는 옵션이 포함되며, 이는 부여 날짜의 나스닥 글로벌 마켓 종가와 일치합니다.
이 옵션은 나스닥 상장 규칙 5635(c)(4)에 따라 회사의 2022년 고용 유도 인센티브 상에 따라 부여되었습니다. 이러한 10년 만기 옵션은 4년에 걸쳐 점진적으로 부여되며, 첫 번째 연도 후 25%가 부여되고 나머지 75%는 이후 3년 동안 매달 부여됩니다. 이는 고용이 지속되는 조건입니다.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) a annoncé que son Comité de Rémunération a accordé des options d'achat d'actions à deux nouveaux employés embauchés le 2 janvier 2025. Les attributions comprennent des options pour acheter 45 000 actions ordinaires à un prix d'exercice de 3,00 $ par action, correspondant au prix de clôture sur le marché mondial Nasdaq à la date de l'attribution.
Les options ont été accordées dans le cadre du Plan d'Incitation à l'Emploi 2022 de l'entreprise, conformément à la Règle de Cotation Nasdaq 5635(c)(4). Ces options d'une durée de 10 ans seront acquises sur une période de quatre ans, avec 25 % acquises après la première année et les 75 % restants acquises mensuellement sur les trois années suivantes, sous réserve de continuation de l'emploi.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) hat bekannt gegeben, dass ihr Vergütungsausschuss am 2. Januar 2025 Aktienoptionen an zwei neu eingestellte Mitarbeiter gewährt hat. Die Zuweisungen umfassen Optionen zum Kauf von 45.000 Stammaktien zu einem Ausübungspreis von 3,00 $ pro Aktie, was dem Schlusskurs am Nasdaq Global Market am Zuteilungsdatum entspricht.
Die Optionen wurden im Rahmen des Anreizplans für die Beschäftigung 2022 des Unternehmens gewährt, gemäß der Nasdaq-Listing-Regel 5635(c)(4). Diese 10-Jahres-Optionen werden über einen Zeitraum von vier Jahren fällig, wobei 25% nach dem ersten Jahr und die verbleibenden 75% monatlich über die folgenden drei Jahre fällig werden, vorausgesetzt, die Beschäftigung wird fortgesetzt.
- None.
- None.
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on January 2, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 45,000 shares of the Company’s common stock to two newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate, azenosertib (ZN-c3), is a potentially first-in-class and best-in-class WEE1 inhibitor for advanced solid tumors. Azenosertib is being evaluated as a monotherapy and in combination across multiple clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types and in combination with several chemotherapy backbones. As part of its azenosertib clinical development program, the Company is exploring enrichment strategies targeting tumors of high genomic instability, such as Cyclin E1 positive tumors, homologous recombination deficient tumors and tumors with oncogenic driver mutations. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
Contacts:
Elizabeth Hickin
Vice President, Investor Relations
ehickin@zentalis.com
FAQ
What is the exercise price of ZNTL's new stock options granted on January 2, 2025?
How many shares are covered by ZNTL's January 2025 inducement stock options?
What is the vesting schedule for ZNTL's January 2025 inducement stock options?
How long is the term of ZNTL's January 2025 inducement stock options?
